The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The utility and Lebanon plan to fund the six-year project with loans low-interest from Indiana’s Drinking Water State ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms ...

The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and UnitedHealth Group Inc., alleging that they artificially pumped up prices of insulin ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients toward higher-priced insulin in order to reap ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes ...